Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenobarbital versus usual care for alcohol withdrawal syndrome in ICU
ACTRN12625000320459Phase 4Active, not recruiting
- Sponsor
- Royal Melbourne Hospital
- Start
- Aug 2025
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of phenobarbital in alcohol withdrawal syndrome (AWS) (3 arms), sponsored by Royal Melbourne Hospital. Primary endpoint: Feasibility. Started Aug 2025; status: active, not recruiting.
02
Drugs
phenobarbital
03
Conditions
alcohol withdrawal syndrome (AWS)
Beyond the preview
Go deeper on ACTRN12625000320459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000320459.